Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Boris Kovalenko

Orthopaedic Surgery Auburn, ME Medical Doctor

NPI 1366838278 CMS profile 7946537

15 Gracelawn Rd Ste 101, Auburn, ME 04210

Open in the dashboard

General payments

$25,938

114 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Boris Kovalenko of Auburn, ME is reported in the CMS Open Payments database as having received $25,938 across 114 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $896 11
2024 General $496 12
2023 General $4,009 26
2022 General $1,368 22
2021 General $11,523 40
2020 General $7,645 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Boris Kovalenko
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Boris Kovalenko were reported at $896. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Boris Kovalenko Orthopaedic Surgery median Middle half National median
2019 $0 $644 $140–$2,844 $163
2020 $7,645 $312 $75–$1,860 $114
2021 $11,523 $520 $117–$2,495 $132
2022 $1,368 $598 $128–$2,731 $149
2023 $4,009 $461 $128–$2,264 $160
2024 $496 $497 $134–$2,475 $164
2025 $896 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Smith+Nephew, Inc. $22,128 61 payments
  2. Zimmer Biomet Holdings, Inc. $2,058 25 payments
  3. Stryker Corporation $1,429 16 payments
  4. Bioventus LLC $106 5 payments
  5. DePuy Synthes Sales Inc. $99 1 payment
  6. Medical Device Business Services, Inc. $58 2 payments
  7. Ferring Pharmaceuticals Inc. $31 2 payments
  8. Djo, LLC $19 1 payment
  9. Dynasplint Systems Inc. $10 1 payment

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Education $15,000 2 payments
  2. Food and Beverage $7,238 103 payments
  3. Travel and Lodging $3,699 9 payments
Products named General payments · program years 2020–2025
  1. JOURNEY $2,604 5 payments
  2. OR3O Dual Mobility $2,604 5 payments
  3. RI Hip Navigation $2,604 5 payments
  4. JOURNEY II $2,145 17 payments
  5. TANDEM $1,560 3 payments
  6. POLARSTEM $1,478 8 payments
  7. CORI $1,419 8 payments
  8. LEGION Revision $1,254 10 payments
  9. REAL INTELLIGENCE $1,129 19 payments
  10. POLAR3 $938 5 payments
  11. Other $6,610 84 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

721

Median for Orthopedic Surgery: 203

Drug cost

$4,593

Median for Orthopedic Surgery: $1,433

Branded share of claims

5.3%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone Hcl Generic 226 $1,521
Lidocaine Generic 18 $1,039
Meloxicam Generic 109 $485
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 26 $388
Diclofenac Sodium Generic 14 $243
Methylprednisolone Generic 23 $162
Hydromorphone Hcl Generic 16 $113
Amoxicillin Generic 147 $110
Cefadroxil Generic 17 $106
Ondansetron Hcl Generic 21 $103

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$70,341

Medicare's payments for the services billed

Medicare patients

198

Average age 74

Services billed

426

128 women, 70 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 72%
Depression 33%
Diabetes 31%
Chronic kidney disease 26%
Ischemic heart disease 24%
COPD 18%
Heart failure 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

114 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Maine

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record